Surrozen Inc Total Assets
Surrozen Inc total assets. Based on the latest financial reports, Surrozen Inc (SRZN) holds total assets worth $115.61 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Surrozen Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Surrozen Inc (2019–2025)
Total assets of Surrozen Inc from 2019 to 2025. This chart illustrates how Surrozen Inc's total assets have evolved over time, based on quarterly financial data. See Surrozen Inc (SRZN) stock price for real-time trading data and today's change.
Surrozen Inc - Asset Composition Analysis
Surrozen Inc Total Assets Breakdown (December 2025)
Surrozen Inc total assets breakdown as of December 2025. Surrozen Inc's total assets of $115.61 Million consist of 92.7% current assets and 7.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 90.4% |
| Accounts Receivable | $208.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Surrozen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore SRZN working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Surrozen Inc's current assets represent 92.7% of total assets in 2025, an increase from 69.2% in 2019.
- Cash Position: Cash and equivalents constituted 90.4% of total assets in 2025, up from 68.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Surrozen Inc Competitors by Total Assets
Key competitors of Surrozen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Surrozen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.14 | 16.41 | 9.09 |
| Quick Ratio | 12.14 | 16.41 | 9.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $100.39 Million | $88.49 Million | $101.46 Million |
Surrozen Inc - Advanced Valuation Insights
This section examines the relationship between Surrozen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.50 |
| Latest Market Cap to Assets Ratio | 2.46 |
| Asset Growth Rate (YoY) | 103.7% |
| Total Assets | $98.73 Million |
| Market Capitalization | $243.06 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Surrozen Inc's assets at a significant premium (2.46x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Surrozen Inc's assets grew by 103.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Surrozen Inc (2019–2025)
The table below shows the annual total assets of Surrozen Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $98.73 Million | +103.70% |
| 2024-12-31 | $48.47 Million | +5.18% |
| 2023-12-31 | $46.08 Million | -48.48% |
| 2022-12-31 | $89.44 Million | -34.80% |
| 2021-12-31 | $137.17 Million | +121.03% |
| 2020-12-31 | $62.06 Million | +46.08% |
| 2019-12-31 | $42.48 Million | -- |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, … Read more